Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 458
- Registration Number
- NCT05230615
- Locations
- 🇮🇹
Novo Nordisk Investigational Site, Sesto San Giovanni, Italy
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 194
- Registration Number
- NCT05230589
- Locations
- 🇸🇦
Specialized Medical Cente, Riyadh, Saudi Arabia
🇸🇦Master Centre for Saudi, Riyadh, Saudi Arabia
A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People
- Conditions
- Healthy VolunteersType 2 Diabetes
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 546
- Registration Number
- NCT05227196
- Locations
- 🇺🇸
Altasciences Clinical LA, Inc., Cypress, California, United States
🇺🇸Altasciences Clinical Kansas, Inc., Overland Park, Kansas, United States
🇨🇦Altasciences Company Inc., Montreal, Quebec, Canada
China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 887
- Registration Number
- NCT05221580
- Locations
- 🇨🇳
NIS-The First People's Hospital of Yulin City, Yulin, Guangxi, China
🇨🇳NIS-Third Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
🇨🇳NIS-Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
A Study in Healthy Participants Investigating Biomarkers After Exposure to Heparin When Heparin is Administered in the Fasted State or After a High-fat Meal. Heparin, a Registered Drug, is an Anticoagulant (Blood Thinner) That Prevents the Formation of Blood Clots.
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 12
- Registration Number
- NCT05178550
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands
A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: NNC0480-0389 10 mg/mLDrug: NNC0480-0389 30 mg/mLDrug: Microgynon®
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 27
- Registration Number
- NCT05153564
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 269
- Registration Number
- NCT05153590
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Soeborg, Denmark
A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 500
- Registration Number
- NCT05144984
- Locations
- 🇭🇺
Kaposi Mór Oktató Kórház, Kaposvár, Hungary
🇭🇺Markusovszky Egyetemi Oktatókórház, Szombathely, Hungary
🇭🇺Szent Borbála Kórház, Tatabánya, Hungary
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
- Conditions
- Haemophilia A and B With and Without Inhibitors
- Interventions
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 90
- Registration Number
- NCT05135559
- Locations
- 🇷🇴
Spitalul Clinic Judetean De Urgenta Bihor, Oradea, Romania
🇷🇺Children Regional Clinical Hospital, Krasnodar, Russian Federation
🇷🇺Morozovskaya municipal children hospital, Moscow, Russian Federation
A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes Pharmacokinetics and Pharmacodynamics: How Insulin NNC0363-0845 is Transported Throughout the Body and How It Works
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 30
- Registration Number
- NCT05134987
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria